National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.

[1]  G. Guyatt,et al.  A menopause-specific quality of life questionnaire: development and psychometric properties. , 1996, Maturitas.

[2]  K. Igarashi,et al.  Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane. , 2007, Bone.

[3]  J. Cuzick,et al.  Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. , 2007, Journal of the National Cancer Institute.

[4]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[5]  D. A. Quistberg,et al.  Prescription of tamoxifen for breast cancer prevention by primary care physicians. , 2006, Archives of internal medicine.

[6]  Shiuan Chen,et al.  Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. , 2006, Cancer research.

[7]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[8]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[9]  J. Costantino,et al.  Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[10]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[11]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[12]  T. Whelan,et al.  Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robert B Livingston,et al.  Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. , 2005, Journal of the National Cancer Institute.

[14]  K. Helzlsouer,et al.  Breast carcinoma chemoprevention in the community setting , 2005, Cancer.

[15]  J. Cuzick.  Aromatase inhibitors for breast cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Baum,et al.  Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.

[17]  James N Ingle,et al.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Cummings,et al.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. , 2004, Journal of the National Cancer Institute.

[19]  P. Lønning,et al.  A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer* , 2004, The New England journal of medicine.

[20]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[21]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[22]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[23]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[24]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[25]  S. Cummings,et al.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[27]  J. Dixon,et al.  Local endocrine effects of aromatase inhibitors within the breast , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  J. Costantino,et al.  Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. , 2001, Clinical breast cancer.

[29]  J. Soudon.  Comparison of in vitro exemestane activity versus other antiaromatase agents. , 2000, Clinical breast cancer.

[30]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[31]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[32]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[33]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .